Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

8.380
-0.175-2.05%
Volume:338.00K
Turnover:2.86M
Market Cap:8.12B
PE:-60.05
High:8.530
Open:8.425
Low:8.360
Close:8.555
52wk High:15.750
52wk Low:6.230
Shares:969.00M
HK Float Shares:969.00M
Volume Ratio:0.37
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.140
ROE:-6.43%
ROA:-4.42%
PB:4.08
PE(LYR):-60.05
PS:12.33

Loading ...

Hang Seng Tech Index Extends Losses to 2%, Knowledge Atlas and Baidu Lead Declines

Deep News
·
Jul 14

ALPHAMAB-B pares 0.02% of outstanding shares in June amid HKD1.11 million buy-back

Bulletin Express
·
Jul 07

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Alphamab Oncology AGM: Shareholders Endorse All 2026 Resolutions

Bulletin Express
·
Jun 12

BUZZ-Alphamab climbs most in over 8 weeks on progress of breast cancer treatment

Reuters
·
Jun 11

Alphamab-B Shares Surge on Positive Phase III Trial Results for Breast Cancer Treatment

Stock News
·
Jun 11

Alphamab Says Phase 3 Study of Breast Cancer Drug Meets Primary Endpoint

MT Newswires Live
·
Jun 11

Hong Kong Market Preview: US May CPI Rises 4.2% Year-on-Year; MIIT to Boost R&D for High-End Optoelectronic Chips

Stock News
·
Jun 11

BRIEF-Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint

Reuters
·
Jun 10

Alphamab-B's Phase III Trial for KN026 in First-Line HER2-Positive Advanced Breast Cancer Hits Primary Endpoint

Stock News
·
Jun 10

Alphamab: Anbenitamab Phase III Trial Hits Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer

Bulletin Express
·
Jun 10

Alphamab Oncology says phase III trial of Anbenitamab plus albumin-bound docetaxel meets primary endpoint in first-line HER2+ advanced breast cancer

Reuters
·
Jun 10

Alphamab Oncology - Phase Iii Clinical Study of Anbenitamab (Kn026) as First-Line Treatment for Her2+ Advanced Breast Cancer Met Primary Endpoint

THOMSON REUTERS
·
Jun 10

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

BRIEF-Alphamab Oncology Says CEO Buys 554,000 Shares On June 4

Reuters
·
Jun 05

ALPHAMAB-B Announces Share Purchases by Executive Director and Management

Deep News
·
Jun 05

Alphamab-B Executes Share Buyback, Spending HK$1.11 Million

Stock News
·
Jun 05

Alphamab Oncology: CEO Xu Ting Leads HK$4.99 Million Share Purchase; Post-Deal Stake Rises to 32.4%

Bulletin Express
·
Jun 05

Alphamab Oncology - CEO DR. Xu Ting Purchases 554,000 Shares on Open Market on June 4, 2026

THOMSON REUTERS
·
Jun 05

Alphamab Oncology - Aggregate Consideration for Share Purchases Totals HK$4.99 Mln at HK$7.375 per Share

THOMSON REUTERS
·
Jun 05